Trade Report: Today, Omeros Corporation’s (OMER) “Buy” Rating Reaffirmed at WBB Securities

Today, Omeros Corporation’s (OMER) “Buy” Rating Reaffirmed at WBB Securities

WBB Securities restated their buy rating on shares of Omeros Corporation (NASDAQ:OMER) in a research note published on Monday. The firm currently has a $75.00 price target on the biopharmaceutical company’s stock.

OMER has been the topic of a number of other reports. Zacks Investment Research cut shares of Omeros Corporation from a hold rating to a sell rating in a report on Wednesday, October 12th. Cantor Fitzgerald reaffirmed a buy rating and issued a $21.00 target price on shares of Omeros Corporation in a report on Wednesday, August 10th. FBR & Co reaffirmed an outperform rating and issued a $38.00 target price on shares of Omeros Corporation in a report on Wednesday, June 29th. Maxim Group reaffirmed a buy rating and issued a $30.00 target price on shares of Omeros Corporation in a report on Thursday, July 28th. Finally, Wedbush reaffirmed an outperform rating and issued a $56.00 target price (down from $62.00) on shares of Omeros Corporation in a report on Thursday, August 11th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company has a consensus rating of Buy and an average price target of $32.45.

Omeros Corporation (NASDAQ:OMER) traded down 1.645% during trading on Monday, reaching $7.475. 158,801 shares of the company’s stock were exchanged. The stock has a 50-day moving average price of $10.51 and a 200 day moving average price of $11.63. The firm’s market capitalization is $293.72 million. Omeros Corporation has a 52 week low of $7.26 and a 52 week high of $16.80.

Omeros Corporation (NASDAQ:OMER) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.18. The business earned $10 million during the quarter, compared to analyst estimates of $9.80 million. The business’s revenue was up 212.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.44) earnings per share. Equities research analysts forecast that Omeros Corporation will post ($1.55) earnings per share for the current fiscal year.

In other Omeros Corporation news, VP Marcia S. Kelbon sold 16,000 shares of the business’s stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $10.91, for a total transaction of $174,560.00. Following the sale, the vice president now directly owns 179,597 shares in the company, valued at approximately $1,959,403.27. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Marcia S. Kelbon sold 15,900 shares of the business’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $11.56, for a total transaction of $183,804.00. Following the sale, the vice president now owns 179,497 shares in the company, valued at $2,074,985.32. The disclosure for this sale can be found here. Company insiders own 13.60% of the company’s stock.

Several large investors have recently modified their holdings of the company. BlackRock Advisors LLC raised its stake in shares of Omeros Corporation by 1.0% in the second quarter. BlackRock Advisors LLC now owns 17,415 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 173 shares during the last quarter. State Board of Administration of Florida Retirement System raised its stake in shares of Omeros Corporation by 1.2% in the second quarter. State Board of Administration of Florida Retirement System now owns 30,737 shares of the biopharmaceutical company’s stock valued at $323,000 after buying an additional 351 shares during the last quarter. Nationwide Fund Advisors raised its stake in shares of Omeros Corporation by 0.9% in the second quarter. Nationwide Fund Advisors now owns 67,255 shares of the biopharmaceutical company’s stock valued at $708,000 after buying an additional 631 shares during the last quarter. Gradient Investments LLC raised its stake in shares of Omeros Corporation by 3.3% in the third quarter. Gradient Investments LLC now owns 25,285 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 814 shares during the last quarter. Finally, ProShare Advisors LLC raised its stake in shares of Omeros Corporation by 2.8% in the second quarter. ProShare Advisors LLC now owns 33,656 shares of the biopharmaceutical company’s stock valued at $354,000 after buying an additional 915 shares during the last quarter. Institutional investors own 48.04% of the company’s stock.

Omeros Corporation Company Profile

Related posts

Leave a Comment